Has the AMA announced new CPT codes to report for the Novavax COVID-19 vaccine?

Yes. On May 4, 2021, the AMA announced the creation of 3 new CPT codes that will be used to report the Novavax COVID-19 vaccine and its administration. It is extremely important to note that these CPT codes are not yet active. The codes will become effective if and when the Novavax COVID-19 vaccine receives either full approval or an Emergency Use Authorization (EUA) from the FDA. We have included the long descriptions for the new codes below for your convenience.

Novavax COVID-19 vaccine product code:
91304: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use

Novavax COVID-19 vaccine administration codes:
0041A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose

0042A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose

We will provide any updates to the status of these codes, payment information and any other pertinent details if and when they are made available by the AMA and/or CMS.

AMA Press Release, AMA announces update to COVID-19 vaccine CPT codes:
https://www.ama-assn.org/press-center/press-releases/ama-announces-update-covid-19-vaccine-cpt-codes-0